BETH ISRAEL DEACONESS MEDICAL CENTER
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer is a funding opportunity from BETH ISRAEL DEACONESS MEDICAL CENTER, up to 395509, closing May 31, 2028.
May 31, 2028
(670d left)Overview
Androgen deprivation remains the standard systemic treatment for prostate cancer (PCa) that has spread beyond the prostate, but most patients progress to metastatic castration-resistant prostate cancer (mCRPC). Many of these tumors will respond to abiraterone or to second generation AR antagonists, but resistance…